Current review panels

I1a - Biomarkers and Genomics

Including genomics, proteomics, metabolomics (and other ‘omics’), high-throughput sequencing, bioinformatics, diagnostic, prognostic and predictive biomarkers, circulating tumour cells.

Panel meeting: December 5, 2016

Harriet Feilotter, PhD (Chair)	Queen’s University Kingston, ON
Jane Bayani, PhD	Ontario Institute for Cancer Research Toronto, ON
Nicolas Crapoulet, PhD	Atlantic Cancer Research Institute Moncton, NB
Andrew Emili, PhD	University of Toronto Toronto, ON
Michael Hendzel, PhD	University of Alberta Edmonton, AB
Thomas Kislinger, PhD	Princess Margaret Cancer Centre - UHN Toronto, ON
Julian Lum, PhD	BC Cancer Agency Vancouver, BC
Leigh Murphy, PhD	Manitoba Institute of Cell Biology Winnipeg, MB
Kirill Rosen, PhD	Dalhousie University Halifax, NS
Robert Sladek, MD	McGill University Montreal, QC
Zhaolin Xu, MD	Dalhousie University Halifax, NS
Gelareh Zadeh, MD/PhD	The Toronto Hospital (Western Division) - UHN Toronto, ON
Hansen He, PhD (Scientific Officer)	Princess Margaret Cancer Centre - UHN Toronto, ON
Scott Bratman, MD/PhD (Scientific Officer)	Princess Margaret Cancer Centre - UHN Toronto, ON
Tanya Gallant (Community Representative)	Canadian Cancer Society - PEI Division
Mai Tran (Community Representative)	Canadian Cancer Society - Alberta/NWT Division

 

I1b - Gene Regulation & Cell Biology

Including mechanisms of transcriptional control, epigenetics, chromatin structure and function, translational control, RNA biology, post-translational modifications, telomere function, DNA damage and repair, organellar biology, model organisms, angiogenesis, cell migration, cell invasion, tumour environment.

Panel meeting: December 8, 2016

Peter Greer, PhD (Chair)	Queen's University Kingston, ON
Kristin Baetz, PhD	University of Ottawa Ottawa, ON
Peter Black, MD	University of British Columbia Vancouver, BC
David Brindley, PhD	University of Alberta Edmonton, AB
Elizabeth Conibear, PhD	University of British Columbia Vancouver, BC
Richard Fahlman, PhD	University of Alberta Edmonton, AB
Gerardo Ferbeyre, PhD	University of Montreal Montreal, QC
Imed Gallouzi, PhD	McGill University Montreal, QC
Anne-Claude Gringas, PhD	Mount Sinai Hospital Toronto, ON
Benjamin Kwok, PhD	Institute for Research in Immunology and Cancer (IRIC) Montreal, QC
Mathieu Lupien, PhD	Princess Margaret Cancer Centre - UHN Toronto, ON
Jane McGlade, PhD	The Hospital for Sick Children Toronto, ON
Gilbert Prive, PhD	University Health Network Toronto, ON
Uri Tabori, MD	The Hospital for Sick Children Toronto, ON
Yojiro Yamanaka, PhD	McGill University Montreal, QC
Michael Downey, PhD (Scientific Officer)	University of Ottawa Ottawa, ON
Paul Kongkham, MD/PhD (Scientific Officer)	University Health Network Toronto, ON
Dawn Ashforth (Community Representative)	Canadian Cancer Society - Ontario Division
John Sterns (Community Representative)	Canadian Cancer Society - Ontario Division

 

I2 - Imaging and Technology Development

Including platform and tool development, systems biology, magnetic resonance imaging (MRI), positron emission tomography (PET), ultrasound, computer tomography (CT), radiobiology, radiotherapy, photodynamic therapy (PDT), optical imaging, microfluidics, nanotechnology.

Panel meeting: December 12, 2016

Aaron Fenster, PhD (Chair)	Robarts Research Institute London, ON
David Juncker, PhD	McGill University Montreal, QC
Marianna Koritzinsky, PhD	Princess Margaret Cancer Centre - UHN Toronto, ON
Piotr Kozlowski, PhD	University of British Columbia Vancouver, BC
Jonathan Lovell, PhD	University at Buffalo Buffalo, NY
Cynthia Menard, MD	Centre Hospitalier de l’Universite de Montreal Montreal, QC
Alan Nichol, MD	BC Cancer Agency Vancouver, BC
Mark Niedre, PhD	Northeastern University Boston, MA
Christopher Phenix, PhD	University of Saskatoon Saskatoon, SK
Paul Schaffer, PhD	TRIUMF Vancouver, BC
Shiladitya Sengupta, PhD	Brigham and Women's Hospital Cambridge, MA
Jack Tuszynski, PhD	University of Alberta Edmonton, AB
Kazuhiro Yasufuku, MD/PhD	Toronto General Hospital - UHN Toronto, ON
Haishan Zeng, PhD	BC Cancer Agency Vancouver, BC
Gang Zheng, PhD	Princess Margaret Cancer Centre - UHN Toronto, ON
Christopher Moraes, PhD (Scientific Officer)	McGill University Montreal, QC
Aaron Ward, PhD (Scientific Officer)	London Health Sciences Centre London, ON
Sean Nurmsoo (Community Representative)	Canadian Cancer Society - Nova Scotia Division
Yalda Hazrat (Community Representative)	Canadian Cancer Society - BC/Yukon Division

 

I3 - Immunology, Signalling and Stem Cells

Including metastasis, hormone-sensitive pathways, growth-factor mediated signalling, immunotherapies, viral therapeutics, cancer stem cells, signal transduction, innate immunity and infection, tumour antigens, immune surveillance, hematopoiesis.

Panel meeting: December 9, 2016

Jayne Danska, PhD (Chair)	The Hospital for Sick Children Toronto, ON
Ninan Abraham, PhD	University of British Columbia Vancouver, BC
David Brooks, PhD	Princess Margaret Cancer Centre - UHN Toronto, ON
David Evans, PhD	University of Alberta Edmonton, AB
Spencer Gibson, PhD	University of Manitoba Winnipeg, MB
Michael Gold, PhD	University of British Columbia Vancouver, BC
Norman Iscove, MD/PhD	Princess Margaret Cancer Centre - UHN Toronto, ON
Kevin Kane, PhD	University of Alberta Edmonton, AB
Jean Marshall, PhD	Dalhousie University Halifax, NS
Mark Minden, MD/PhD	Princess Margaret Cancer Centre - UHN Toronto, ON
Luc Sabourin, PhD	Ottawa Hospital Research Institute Ottawa, ON
Vuk Stambolic, PhD	Princess Margaret Cancer Centre - UHN Toronto, ON
William Stanford, PhD	Ottawa Hospital Research Institute Ottawa, ON
David Stojdl, PhD	Children's Hospital of Eastern Ontario Ottawa, ON
Jacques Thibodeau, PhD	University of Montreal Montreal, QC
Patrick O’Donoghue, PhD (Scientific Officer)	Western University London, ON
Jean Wang, MD/PhD (Scientific Officer)	Princess Margaret Cancer Centre - UHN Toronto, ON
Sandy McDonald (Community Representative)	Canadian Cancer Society - Ontario Division
Genevieve Roussy (Community Representative)	Canadian Cancer Society - New Brunswick Division

 

I4 - Novel Therapeutics

Including drug candidates, rational drug design, hit and target validation, compound screening, medicinal chemistry, pharmacology, drug delivery systems, drug transport, drug resistance, combination therapies and pharmacogenomics.

Panel meeting: December 1, 2016

Craig Thomas, PhD (Chair)	National Institutes of Health Rockville, MD
Philippe Bedard, MD	Princess Margaret Cancer Centre - UHN Toronto, ON
Robert Britton, PhD	Simon Fraser University Burnaby, BC
Daniel De Carvalho, PhD	Princess Margaret Cancer Centre - UHN Toronto, ON
Mark Glover, PhD	University of Alberta Edmonton, AB
Matthew Hall, PhD	National Institutes of Health Rockville, MD
Philip Hieter, PhD	University of British Columbia Vancouver, BC
Jose Monzon, MD/PhD	Tom Baker Cancer Centre Calgary, AB
Kevin Petrecca, MD/PhD	McGill University Montreal, QC
Lynne-Marie Postovit, PhD	University of Alberta Edmonton, AB
Michel Roberge, PhD	University of British Columbia Vancouver, BC
Donna Senger, PhD	University of Calgary Calgary, AB
Christian Steidl, MD/PhD	BC Cancer Agency Vancouver, BC
Josie Ursini-Siegel, PhD	Lady Davis Institute Montreal, QC
Murray Webb, PhD	The Centre for Drug Research and Development (CDRD) Vancouver, BC
Jeremy Wulff, PhD	University of Victoria Victoria, BC
Rebecca Laposa, PhD (Scientific Officer)	University of Toronto Toronto, ON
Daniel Schramek, PhD (Scientific Officer)	Mount Sinai Hospital Toronto, ON
Nancy McFadden (Community Representative)	Canadian Cancer Society - Ontario Division
Angie Woodcock (Community Representative)	Canadian Cancer Society - Ontario Division

 

I5 - Prevention and Quality of Life 

Including epidemiology, prevention interventions, lifestyle and environmental risk factors, health economics, health services, quality of life, survivorship, palliative care, psychosocial issues, knowledge translation and exchange.

Panel meeting: June 2, 2016

Patricia Parker, PhD (Chair)	Memorial Sloan-Kettering Cancer Center New York, NY
Catherine Alfano, PhD	American Cancer Society Washington, DC
Angel Aranout, MD	Ottawa Hospital Research Institute Ottawa, ON
Lisa Barbera, MD	Sunnybrook Research Institute Toronto, ON
Hugh Davies, PhD	University of British Columbia Vancouver, BC
Karen Kopciuk, PhD	Alberta Health Services Calgary, AB
Jane McCusker, MD/DrPH	McGill University Montreal, QC
Jennifer O'Loughlin, PhD	University of Montreal Montreal, QC
Robert Reid, PhD/MBA	University of Ottawa Heart Institute Ottawa, ON
Catherine Sabiston, PhD	University of Toronto Toronto, ON
Jonathan Sussman, MD	Juravinski Cancer Centre Hamilton, ON
Alice Wei, MD	Princess Margaret Cancer Centre - UHN Toronto, ON
Jennifer Brunet, PhD (Scientific Officer)	University of Ottawa Ottawa, ON
Brita Danielson, MD (Scientific Officer)	Alberta Health Services Edmonton, AB
Stephen Ng (Community Representative)	Canadian Cancer Society - BC/Yukon Division

 

LOI review teleconference: June 29, 2017

Panel meeting: November 29, 2017

John Bell, PhD (Co-Chair)	Ottawa Hospital Research Institute Ottawa, ON
Craig Earle, MD (Co-Chair)	Sunnybrook Research Institute Toronto, ON
Stephane Angers, PhD	University of Toronto Toronto, ON
Mick Bhatia, PhD	McMaster University Hamilton, ON
Deborah Bowen, PhD	University of Washington Seattle, WA
Grant Brown, PhD	University of Toronto Toronto, ON
Andrew Craig, PhD	Queen’s University Kingston, ON
Shoukat Dedhar, PhD	BC Cancer Agency Vancouver, BC
Mary Jane Esplen, PhD/RN	Princess Margaret Cancer Centre – UHN Toronto, ON
Steven Gallinger, MD	Mount Sinai Hospital Toronto, ON
Trang Hoang, PhD	IRIC Montreal, QC
Robert Holt, PhD	BC Cancer Agency Vancouver, BC
Nada Jabado, MD/PhD	McGill University Montreal, QC
Rama Khokha, PhD	Princess Margaret Cancer Centre – UHN Toronto, ON
Robert Korneluk, PhD	Children’s Hospital of Eastern Ontario Ottawa, ON
Sylvain Meloche, PhD	University of Montreal Montreal, QC
Anne-Marie Mes-Masson, PhD	Centre de recherche du CHUM Montreal, QC
Karen Mossman, PhD	McMaster University Hamilton, ON
Brad Nelson, PhD	BC Cancer Agency Victoria, BC
Geoff Porter, MD	Dalhousie University Halifax, NS
Poul Sorensen, MD/PhD	BC Cancer Agency Vancouver, BC
Lillian Sung, MD/PhD	The Hospital for Sick Children Toronto, ON
Sandy McDonald (Community Representative)	Canadian Cancer Society - Ontario Division
Rabeya Sharmin (Community Representative)	Canadian Cancer Society - Ontario Division

Panel meeting: October 5, 2017

Christine Friedenreich, PhD (Chair)	Alberta Health Services Calgary, AB
Michael Chaiton, PhD	University of Toronto Toronto, ON
Andrea Cherrington, MD	University of Alabama at Birmingham Birmingham, AL
Sean Cleary, MD	Mayo Clinic Rochester, MN
Hugh Davies, PhD	University of British Columbia Vancouver, BC
Emmanuel Guindon, PhD	McMaster University Hamilton, ON
Julia Knight, PhD	Mount Sinai Hospital Toronto, ON
Karen Kopciuk, PhD	Alberta Health Services Calgary, AB
Charles Matthews, PhD	National Cancer Institute Bethesda, MD
Colleen McBride, PhD	Emory University Atlanta, GA
Lawrence Paszat, MD	University of Toronto Toronto, ON
Mark Purdue, PhD	National Cancer Institute Bethesda, MD
Nicolas Wentzensen, MD/PhD	National Cancer Institute Bethesda, MD
Regina Ziegler, PhD	National Cancer Institute Bethesda, MD
Jennifer Brunet, PhD (Scientific Officer)	University of Ottawa Ottawa, ON
Gillian Hanley, PhD (Scientific Officer)	University of British Columbia Vancouver, BC
Joel Finlay (Community Representative)	Canadian Cancer Society - BC/Yukon Division
Elizabeth MacLeod (Community Representative)	Canadian Cancer Society - Ontario Division

LOI review teleconference: September 12, 2017

Panel meeting: January 10, 2018

Jamie Studts, PhD (Chair)	University of Kentucky Lexington, KY
Natasha Leighl, MD (Chair)	Princess Margaret Cancer Centre Toronto, ON
Jessica Burris, PhD	University of Kentucky Lexington, KY
Kristin Campbell, PhD	University of British Columbia Vancouver, BC
Anees Chagpar, MD	Yale University New Haven, CT
Kelvin Chan, MD	Sunnybrook Research Institute Toronto, ON
Winson Cheung, PhD	BC Cancer Agency Vancouver, BC
Kristine Donovan, PhD/MBA	Moffitt Cancer Center and Research Institute Tampa, FL
Wendy Duggleby, PhD	University of Alberta Edmonton, AB
David Eisenstat, MD	University of Alberta Edmonton, AB
Heidi Hamann, PhD	University of Arizona Tucson, AZ
Shelby Langer, PhD	Arizona State University Tucson, AZ
Sophie Lebel, PhD	University of Ottawa Ottawa, ON
Christopher Longo, PhD	McMaster University Hamilton, ON
Paul Nathan, MD	The Hospital for Sick Children Toronto, ON
Suzanne O'Neill, PhD	Georgetown University Washington, DC
Tony Panzarella, MSc	Princess Margaret Cancer Centre Toronto, ON
Tara Schapmire, PhD	University of Louisville School of Medicine Louisville, KY
Allen Sherman, PhD	University of Arkansas for Medical Sciences Little Rock, AR
Sumit Gupta, MD/PhD (Scientific Officer)	The Hospital for Sick Children Toronto, ON
Alexander Louie, MD (Scientific Officer)	Lawson Health Research Institute London, ON
Scott Johnson (Community Representative)	Canadian Cancer Society - Alberta/NWT Division
Cindy Vinall (Community Representative)	Canadian Cancer Society - Ontario Division

Panel meeting: September 15, 2017

David Chambers, PhD (Chair)	National Cancer Institute Rockville, MD
Smita Banerjee, PhD	Memorial Sloan-Kettering Cancer Center New York, NY
Carole Estabrooks, RN/PhD	University of Alberta Edmonton, AB
Anna Gagliardi, PhD	University Health Network Toronto, ON
Monika Krzyzanowska, MD	Princess Margaret Cancer Centre – UHN Toronto, ON
France Légaré, MD/PhD	Laval University Quebec City, QC
Martine Puts, RN/PhD	University of Toronto Toronto, ON
Brenda Sabo, RN/PhD	Dalhousie University Halifax, NS
Janet Squires, RN/PhD	University of Ottawa Ottawa, ON
Marko Simunovic, MD	McMaster University Hamilton, ON
Robin Urquhart, PhD	Dalhousie University Halifax, NS
Jessie-Lee McIsaac, PhD (Scientific Officer)	Dalhousie University Halifax, NS
Stephen Ng (Community Representative)	Canadian Cancer Society - BC/Yukon Division

The Canadian Cancer Society Research Institute is pleased to support the partnership between the CCS Quebec Division, and the Cole Foundation and its partners, to fund research grants in the area of pediatric and young adult leukemia and lymphoma research. The CCSRI will administer the competition on their behalf as per CCSRI processes. Details of the competition can be found here.

Panel meeting: June 5, 2017

Jason Berman, MD (Chair)	Dalhousie University Halifax, NS
Sarah Alexander, MD	The Hospital for Sick Children Toronto, ON
Harold Atkins, MD	Ottawa Hospital Research Institute Ottawa, ON
Jeanette Boudreau, PhD	Dalhousie University Halifax, NS
Todd Druley, MD/PhD	Washington University in St. Louis Saint Louis, MO
Xiaoyan Jiang, MD/PhD	BC Cancer Agency Vancouver, BC
Donna Johnston, PhD	Children's Hospital of Eastern Ontario Ottawa, ON
Mark Minden, MD/PhD	Princess Margaret Cancer Centre – UHN Toronto, ON
Aaron Schimmer, MD/PhD	Princess Margaret Cancer Centre – UHN Toronto, ON
Steven Chan, MD/PhD (Scientific Officer)	University Health Network Toronto, ON

Panel I - Fundamental laboratory and pre-clinical research

Fundamental laboratory and pre-clinical investigations addressing biology of breast cancer, etiology, prevention, early detection, diagnosis, prognosis, treatment (discovery and development), and development and characterization of model systems.

LOI Review meeting: October 13, 2016

Full Application Review meeting: February 27 & 28, 2017 

Jonathan Bramson, PhD (Chair)	McMaster University Hamilton, ON
Paola Marignani, PhD (Vice Chair)	Dalhousie University Halifax, NS
Tommy Alain, PhD*	Children's Hospital of Eastern Ontario Ottawa, ON
Nicolas Bisson, PhD	Université Laval Québec, QC
Ann Dorward, PhD	Memorial University of Newfoundland St. John's, NL
Humphrey Fonge, PhD*	University of Saskatchewan Saskatoon, SK
Leonard Foster, PhD*	University of British Columbia Vancouver, BC
Mitsuru Futakuchi, PhD*	Nagoya City University Nagoya, Japan
Louis Gendron, PhD*	Université de Sherbrooke Sherbrooke, QC
Ing Swie Goping, PhD	University of Alberta Edmonton, AB
Kensuke Hirasawa, PhD	Memorial University of Newfoundland St. John’s, NL
Nagarajan Kannan, PhD	Mayo Clinic Rochester, MN
Thomas Klonisch, PhD	The University of Manitoba Winnipeg, MB
Ujendra Kumar, PhD	University of British Columbia Vancouver, BC
Wan Lam, PhD*	BC Cancer Agency Vancouver, BC
James Lim, PhD*	University of British Columbia Vancouver, BC
Julian Lum, PhD	BC Cancer Agency Victoria, BC
Anthony Magliocco, MD*	L. Lee Moffitt Cancer Centre & Research Institute Tampa, FL
Brian Marples, PhD*	University of Miami Miller School of Medicine Miami, FL
Luke McCaffrey, PhD	McGill University Montreal, QC
David Murray, PhD	University of Alberta Edmonton, AB
Neil O’Brien, PhD*	University of California, Los Angeles Los Angeles, CA
Catherine Pallen, PhD*	University of British Columbia Vancouver, BC
Lawrence Pfeffer, PhD*	The University of Tennessee Memphis, TN
Matthew Sikora, PhD	University of Colorado Denver, CO
John Spinelli, PhD*	BC Cancer Agency Vancouver, BC
Catherine Too, PhD*	Dalhousie University Halifax, NS
Alan Underhill, PhD*	University of Alberta Edmonton, AB
Nelson Wong, PhD	BC Cancer Agency Vancouver, BC
Yuliang Wu, PhD*	University of Saskatchewan Saskatoon, SK
Donald T. Yapp, PhD*	BC Cancer Agency Vancouver, BC
Sheila Singh, MD/PhD (External)	McMaster University Hamilton, ON
Lindsay DeVorkin, PhD (Scientific Officer)	BC Cancer Agency Victoria, BC

* denotes reviewers who participated in the LOI Review Process only

 

Panel II - Clinical, psychosocial, and evaluative research

Clinical projects and evaluative research addressing etiology, prevention, early detection, diagnosis, prognosis, treatment (clinical applications), evaluation of delivery methods and interventions, as well as projects addressing psychosocial issues, supportive care, survivorship, quality of life, behavioural research, cancer control, health systems and outcomes research.

LOI Review meeting: October 14, 2016

Full Application Review meeting: March 1, 2017 

Stephen Chia, MD (Co-Chair)	BC Cancer Agency Vancouver, BC
Craig Earle, MD (Co-Chair)	Sunnybrook Health Sciences Centre Toronto, ON
Samuel Aparicio, PhD	BC Cancer Agency Vancouver, BC
Deanna Attai, MD	University of California Los Angeles Los Angeles, CA
Tavis Campbell, PhD*	University of Calgary Calgary, AB
Karen Gelmon, MD	BC Cancer Agency Vancouver, BC
Esther Green*	Canadian Partnership Against Cancer Toronto, ON
Lee Jones, PhD	Memorial Sloan Kettering Cancer Center New York, NY
Steven Latosinsky, MD	Western University London, ON
Yolanda Madarnas, MD*	Kingston General Hospital Kingston, ON
Carole Mayer, PhD*	Northeast Cancer Centre Sudbury, ON
Alan Nichol, MD*	BC Cancer Agency Vancouver, BC
Susan Peterson, PhD	The University of Texas MD Anderson Cancer Center Houston, TX
Kasmintan Schrader, MD, PhD	University of British Columbia Vancouver, BC
Kristin L. Schreiber, MD, PhD*	Brigham and Women’s Hospital Boston, MA
Abigail Silva, PhD*	Loyola University Chicago Chicago, IL
Savitri Singh-Carlson, PhD	UT Health Science Center at San Antonio San Antonio, TX
Ted Vandenberg, MD*	London Health Sciences Centre London, ON
Rebecca Auer, MD (External)	The Ottawa Hospital Ottawa, ON
Christine Brezden-Masley, MD (External)	St. Michael’s Hospital Toronto, ON
Jay Harris, MD (External)	Harvard Medical School Boston, MA
Andrew Karellas, PhD (External)	University of Arizona Tuscon, AZ
Kara Laing, MD (External)	Memorial University of Newfoundland St. John’s, NL
Nelson Leong, MD (Scientific Officer)	Saskatchewan Cancer Agency Regina, SK

* denotes reviewers who participated in the LOI Review Process only